Silberstein Erica, Taylor Deborah R
Laboratory of Hepatitis and Related Emerging Agents, Center for Biologics Evaluation and Research, US Food and Drug Administration.
Int J Biomed Sci. 2008 Jun;4(2):82-8.
Hepatitis C virus is a flavivirus that infects nearly 2% of the world population. There is no vaccine available and current therapy with interferon and ribavirin is expensive, not well tolerated and effective in only 60% of patients. HCV research has been hampered by the lack of a robust tissue culture system, but recent advances have made virus growth in culture possible. Here we review the current state-of-the-art and the molecular hurdles that have been met and those that still need to be overcome.
丙型肝炎病毒是一种黄病毒,感染了全球近2%的人口。目前尚无可用疫苗,且当前使用干扰素和利巴韦林的治疗方法昂贵、耐受性差,仅对60%的患者有效。由于缺乏强大的组织培养系统,丙型肝炎病毒的研究受到了阻碍,但最近的进展使病毒在培养物中生长成为可能。在此,我们综述了当前的技术水平以及已经遇到和仍需克服的分子障碍。